Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
A phase 2 trial of PM 8.4 mg/m^2 in diffuse large B-cell lymphoma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.
Overview
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) is a phase 2 interventional study registered as NCT05563844 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 74 participants enrolled, started 2022-11-08 and due to reach its primary completion in 2026-12-30. Interventions recorded: PM 8.4 mg/m^2 and PM 11.2 mg/m^2.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialPurinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialA Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialPhase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Shares Diffuse large B-cell lymphoma and the tag pipeline.
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares Diffuse large B-cell lymphoma and the tag pipeline.
- TrialA Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Shares Diffuse large B-cell lymphoma and the tag pipeline.
- TrialA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Shares Diffuse large B-cell lymphoma and the tag pipeline.